SecSonar.com

INmune Bio, Inc. (INMB)

INmune Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

INmune Bio, Inc. (INMB) is a Biotechnology company based in US with a market capitalization of $36.3M. Revenue grew 257.1% year-over-year and free cash flow was negative at -$23.6M. This page tracks INMB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 13 employees · IPO Feb 4, 2019

Valuation

Valuation & price

$1.55 · as of May 17, 2026 · -50.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.54

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$3.16$2.14$1.12Jul 25Dec 25Jul 26Jul 7, 25$2.30Jul 9, 25$2.36Jul 11, 25$2.31Jul 15, 25$2.07Jul 17, 25$2.24Jul 21, 25$2.38Jul 23, 25$2.86Jul 25, 25$2.71Jul 29, 25$3.16Jul 31, 25$2.73Aug 4, 25$2.86Aug 6, 25$2.76Aug 11, 25$2.40Aug 13, 25$2.56Aug 15, 25$2.53Aug 19, 25$2.40Aug 21, 25$2.35Aug 25, 25$2.24Aug 27, 25$2.05Aug 29, 25$2.03Sep 3, 25$1.97Sep 5, 25$1.95Sep 9, 25$1.78Sep 11, 25$1.97Sep 16, 25$1.99Sep 18, 25$1.97Sep 22, 25$1.98Sep 24, 25$1.95Sep 26, 25$2.01Sep 30, 25$2.07Oct 2, 25$2.14Oct 6, 25$2.06Oct 8, 25$2.01Oct 10, 25$1.86Oct 14, 25$1.87Oct 16, 25$1.85Oct 21, 25$1.89Oct 23, 25$1.79Oct 27, 25$1.84Oct 29, 25$1.82Oct 31, 25$1.83Nov 4, 25$1.72Nov 6, 25$1.63Nov 10, 25$1.58Nov 12, 25$1.52Nov 14, 25$1.42Nov 18, 25$1.50Nov 20, 25$1.49Nov 25, 25$1.52Nov 28, 25$1.74Dec 2, 25$1.57Dec 4, 25$1.88Dec 8, 25$2.04Dec 10, 25$2.23Dec 12, 25$2.01Dec 16, 25$1.89Dec 18, 25$1.82Dec 22, 25$1.88Dec 24, 25$1.77Dec 29, 25$1.66Jan 2, 26$1.54Jan 6, 26$1.56Jan 8, 26$1.53Jan 12, 26$1.47Jan 14, 26$1.54Jan 16, 26$1.73Jan 21, 26$1.64Jan 23, 26$1.70Jan 27, 26$1.80Jan 29, 26$1.56Feb 2, 26$1.58Feb 4, 26$1.52Feb 9, 26$1.54Feb 11, 26$1.57Feb 13, 26$1.44Feb 18, 26$1.35Feb 20, 26$1.31Feb 24, 26$1.34Feb 26, 26$1.34Mar 2, 26$1.33Mar 4, 26$1.32Mar 6, 26$1.33Mar 10, 26$1.28Mar 12, 26$1.33Mar 17, 26$1.28Mar 19, 26$1.22Mar 23, 26$1.24Mar 25, 26$1.22Mar 27, 26$1.12Mar 31, 26$1.13Apr 2, 26$1.21Apr 7, 26$1.27Apr 9, 26$1.28Apr 13, 26$1.24Apr 15, 26$1.32Apr 17, 26$1.45Apr 22, 26$1.43Apr 24, 26$1.39Apr 28, 26$1.40Apr 30, 26$1.43May 4, 26$1.48May 6, 26$1.52May 8, 26$1.43May 12, 26$1.39May 14, 26$1.68May 18, 26$1.49May 20, 26$1.41May 22, 26$1.45May 28, 26$1.42Jun 1, 26$1.39Jun 3, 26$1.32Jun 5, 26$1.26Jun 9, 26$1.22Jun 11, 26$1.27Jun 15, 26$1.28Jun 17, 26$1.30Jun 22, 26$1.43Jun 24, 26$1.35Jun 26, 26$1.42Jul 2, 26$1.70
$1.1252-week range$3.16
Loading valuation history…

Fundamentals

Key fundamentals

$36.3M

Market cap

257.1%

Revenue growth (YoY)

100.0%

Gross margin

-$23.6M

Free cash flow (USD)

-$23.7M

Net debt

Net cash position

33.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$11.0KFY 2021$181.0KFY 2022$374.0KFY 2023$155.0KFY 2024$14.0KFY 2025$50.0K
$0$50K

Free cash flow by year

2016 → 2025

FY 2016$-317.4KFY 2017$-861.8KFY 2018$-2.1MFY 2019$-5.4MFY 2020$-8.9MFY 2021$-43.5MFY 2022$-22.7MFY 2023$-12.0MFY 2024$-33.4MFY 2025$-23.6M
-$317.4K-$23.6M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventWarrant Inducement OfferJul 1, 2026Filing
  • 8-K eventRegulatory Meeting UpdateJun 23, 2026Filing
  • 8-K eventStock Incentive Plan AmendedJun 17, 2026Filing
  • 8-K eventPhase 2 Trial ResultsJun 2, 2026Filing
  • 8-K eventFDA Fast Track DesignationMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventAgreement AmendmentMay 5, 2026Filing

Questions

Frequently asked questions

What is INmune Bio, Inc.'s market cap?

INmune Bio, Inc. (INMB) has a market capitalization of $36.3M.

What is INMB's P/E ratio?

A meaningful P/E ratio is not available for INMB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is INMB's price-to-book (P/B) ratio?

INMB trades at 1.54 times book value per share.

Are insiders buying INMB stock?

SEC Form 4 filings show no open-market insider buys at INmune Bio, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ATHE

Alterity Therapeutics Limited

$36.5M

BTAI

BioXcel Therapeutics, Inc.

$37.1M

ALGS

Aligos Therapeutics, Inc.

$35.5M

VERU

Veru Inc.

$37.4M

RNXT

RenovoRx, Inc.

$35M

SABS

SAB Biotherapeutics, Inc.

$34.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.